AIDS researchers, many of whom have been meeting this week in Rome under the auspices of the International AIDS Society, are rightly pleased with the progress they have made. In particular, the use of antiretroviral drugs has not only revolutionised treatment of HIV infection, but also offers the prospect of stopping the spread of the virus. In a matter of weeks, these drugs reduce the number of viruses per millilitre of infected blood from millions to less than 50. That deals with both symptoms and infectivity. Unless a patient stops taking the drugs, or goes on to develop resistance to them, he can expect to live almost as long as an uninfected individual.
……. there is a glimmer of hope on the horizon. To deal with dormant viruses several researchers are taking what sounds like a counterintuitive approach. They are trying to wake the viruses up and so boost, rather than reduce, the amount of active HIV in a patient’s body. Their reasoning is that the now-active viruses will either kill the cells they are in (and thus themselves) or encourage the immune system to attack those cells.
That is the Economist in its latest issue. For more on the details of the state of AIDS research go here.
The Economist’s optimism is supported by empirical data. According to the Vancouver Sun:
HIV patients in Uganda who are receiving regular treatment can expect to live a near-normal lifespan, Canadian researchers have suggested in the world’s first large-scale study to examine HIV patients’ life expectancy in Africa.
After studying 22,315 patients who were using combined antiretroviral therapy (cART), scientists from the B.C. Centre for Excellence in HIV/AIDS along with experts at the Universities of British Columbia and Ottawa found that with early initiation and access to regular treatment, those infected with HIV were living about two-thirds of a normal lifespan.